A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors

NCT07170787 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: IMM2510
BIOLOGICAL: IMM01

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.